3Laehaine J,Yen L, Beauchemin C, et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database [ J ]. BMC Gastroenterol, 2013,30 (13) :23.
4Mitra D,Hodgkins P,Yen L,et al. Association between oral 5 -ASA adherence and health care utilization and costs among patients with active ulcerative colitis [J]. BMC Gastroenterol, 2012,24 ( 12 ) : 132.
5Kane S V, Brixner D, Rubin D T, et al. The challenge of compliance and persistence:focus on ulcerative colitis[ J ]. J Manag Care Pharm, 2008,14( 1 ) :2-12.
6Horv6th G, Farkas K, Holl6si R, et al. Is there any association be- tween impaired health - related quality of life and non - adherence to medical therapy in inflammatory bowel disease? [J]. Scand J Gas- troentero1,2012,47 ( 11 ) : 1298-1303.
7Yen L,Wu J, Hodgkins P L, et al. Medication use patterns and pre- dictors of nonpersistence and nonadherence with oral 5 - aminosali- cylic acid therapy in patients with ulcerative colitis[ J ]. J Manag Care Pharm,2012,18 (9) :701-712.
9Khan N, Abbas A M, Koleva Y N, et al. Long - term mesalamine ma- intenance in ulcerative colitis:which is more important adherence or daily dose [ J ]. Inflamm Bowel Dis ,2013,19 ( 6 ) : 1123-1129.
10Robinson A, Hankins M, Wiseman G, et al. Maintaining stable symp- tom control in inflamnmtory bowel disease:a retrospective analysis of adherence, medication switches and the risk of relapse [ J ]. Aliment Pharmacol Ther,2013,38 (5) :531-538.
